S1800E: LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)
- Title
- LUNGMAP: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (LungMAP Non-Matched Sub-Study)
- Principal Investigator
- Almubarak, Mohammed
- Phase
- II/III
- Age Group
- Adult
- Applicable Disease Sites
- Lung Cancer
- Participating Institutions
- Berkeley Medical Center
- Camden Clark Medical Center
- Mary Babb Randolph Cancer Center
- United Hospital Center
- Wheeling Hospital
- Contacts
- Sabrina Rexroad, RN
- Research Nurse
- Email: sabrina.rexroad1@wvumedicine.org
- Valli White, RN
- Research Nurse
- Phone: +1 304-264-1220
- Email: valli.white@wvumedicine.org
- Maher Kali, MD
- Clinical Research Specialist-WVUCI
- Phone: +1 304-243-7045
- Email: maher.kali@wvumedicine.org
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org
- Nnennaya Opara
- Clinical Research Specialist
- Phone: +1 681-342-1000
- Email: nnennaya.opara1@wvumedicine.org
- Rachel Harper
- Clinical Research Specialist
- Phone: +1 304-293-6066
- Email: rachel.harper@hsc.wvu.edu